GetTopicDetailResponse(id=2dfe96581a, topicName=IL-27, introduction=IL-27, content=null, image=null, comments=1, allHits=2157, url=https://h5.medsci.cn/topic?id=9658, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=35516, tagList=[TagDto(tagId=35516, tagName=IL-27)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265505, encodeId=bb5c2265505d2, content=<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#腫瘤微環(huán)境#</a> <a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>, objectTitle= 讀書報告 | IL-27通過促進CD8+T細胞的持久性和效應功能以增強抗腫瘤能力, objectType=article, longId=877942, objectId=56048e79428c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-using-smartphone-app-in-hospital-office-PEMB8JL.jpg, objectUrl=/article/show_article.do?id=56048e79428c, replyNumber=0, likeNumber=34, createdTime=2025-05-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=56048e79428c, moduleTitle= 讀書報告 | IL-27通過促進CD8+T細胞的持久性和效應功能以增強抗腫瘤能力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=56048e79428c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2250977, encodeId=6a9222509e73e, content=<a href='/topic/show?id=a07f82814ec' target=_blank style='color:#2F92EE;'>#腫瘤免疫治療#</a> <a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>, objectTitle=Nature：IL-27：腫瘤免疫治療的新突破，增強T細胞活力的關鍵因子, objectType=article, longId=862290, objectId=7b51862290f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720361307287_5579292.png, objectUrl=/article/show_article.do?id=7b51862290f3, replyNumber=0, likeNumber=69, createdTime=2025-02-07, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=7b51862290f3, moduleTitle=Nature：IL-27：腫瘤免疫治療的新突破，增強T細胞活力的關鍵因子, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7b51862290f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197937, encodeId=e25d219e93765, content=<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a> <a href='/topic/show?id=ef811132e390' target=_blank style='color:#2F92EE;'>#炎癥性自身免疫疾病#</a>, objectTitle=Front Immunol：中國學者綜述——IL-27的雙刃劍作用：在炎癥性自身免疫疾病中的作用和治療潛力, objectType=article, longId=821081, objectId=9c1f821081cf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240410/1712757436396_5485250.jpg, objectUrl=/article/show_article.do?id=9c1f821081cf, replyNumber=0, likeNumber=95, createdTime=2024-04-11, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9c1f821081cf, moduleTitle=Front Immunol：中國學者綜述——IL-27的雙刃劍作用：在炎癥性自身免疫疾病中的作用和治療潛力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9c1f821081cf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=898628, encodeId=1733898628d8, content=靶向<a href='/topic/show?id=2dfe96581a' target=_blank style='color:#2F92EE;'>#IL-27#</a>用于<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a>治療，這是繼<a href='/topic/show?id=4399103e93a7' target=_blank style='color:#2F92EE;'>#抗血管新生#</a>，<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治療#</a>之后，又一新選擇，以后幾種方法組合，可能會對肝癌帶來一些新的突破。
IL-27抑制劑主要是調(diào)節(jié)<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#腫瘤微環(huán)境#</a>的藥物，可能會與PD-1類藥物存在協(xié)同效應。, objectTitle=FDA授予SRF388治療肝癌的“快速通道資格”, objectType=article, longId=203283, objectId=767f203283c4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201111/1605108661404_5295902.jpeg, objectUrl=/article/show_article.do?id=767f203283c4, replyNumber=0, likeNumber=354, createdTime=2020-11-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767f203283c4, moduleTitle=FDA授予SRF388治療肝癌的“快速通道資格”, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=767f203283c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
